Allegations by a former Daiichi Sankyo sales representative against her ex-employer have resulted in the global pharmaceutical titan agreeing to pay a $39 million settlement to the United States and state Medicaid programs. The former rep filed suit on behalf of the United States under the whistle blower provisions of... Read more »

As Benicar lawsuits continue to escalate across the nation, plaintiffs have petitioned the Judicial Panel on Multidistrict Litigation (JPML) to consolidate similar actions that allege severe gastrointestinal injuries. In a motion filed on December 18, plaintiff Annette Johnson asked the JPML to transfer all federally-filed cases to the Northern District... Read more »

The popular blood pressure drug known as Benicar (olmesartan medoxomil) is becoming increasingly known for its propensity to cause users severe and debilitating abdominal discomfort – reportedly linked to the onset of a condition known as sprue-like enteropathy. Benicar belongs to a class of drugs known as angiotensin receptor blockers,... Read more »

Claims by plaintiffs in Benicar GI side effects lawsuits have recently been given support by a French study that was presented this past June at Digestive Disease Week in Chicago. The study brings to light just how great an impact using the blood pressure medication Benicar for a long term can... Read more »

Angiotensin II type 1 receptor blockers (ARBs) are commonly used in the treatment of hypertension (high blood pressure) and heart failure. Benicar, manufactured by Daiichi Sankyo, is one of the more widely prescribed ARBs since its FDA approval in 2002. Also known by its generic name olmesartan medoxomil, Benicar has... Read more »

Celiac disease has been mysteriously on the rise in recent years but a new study has linked some celiac-like symptoms with the use of olmesartan, a popular blood pressure medication commonly sold under the name Benicar. Benicar is a hypertension medication also known under the generic name olmesartan. It is an angiotensin II receptor... Read more »